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ABSTRACT 
 
OBJECTIVE: The objective of this systematic review is to determine whether or not topical 1% 
pimecrolimus cream is an effective treatment for rosacea. 
 
STUDY DESIGN: Review of three English language primary studies published between 2007 
and 2008. 
 
DATA SOURCES: Randomized, controlled, investigator-blind clinical trials comparing topical 
1% pimecrolimus application to either placebo cream or an untreated portion of the face were 
found using OVID, MEDLINE, and Cochrane Databases.   
 
OUTCOMES MEASURED: Rosacea severity and improvement.  Rosacea severity was assessed 
using the Rosacea Severity Score, set forth by the National Rosacea Society Expert Committee, 
which classifies the severity of erythema, papules, pustules, edema, and telangiectasia on a scale 
of 0 (no symptoms) to 3 (severe symptoms).  Subjective severity scores were assigned using a 
visual analog scale (VAS) to assess rosacea severity on a scale of 0 (clear) to 5 (very severe).  
Rosacea severity was also assessed using a Subjective Severity Assessment (0-100 scale) and an 
investigators’ global assessment of erythema, papules, and total inflammatory lesions. 
 
RESULTS:  Dichotomous data from the Karabulut et al. study did not show the use of topical 
1% pimecrolimus cream to result in statistically significant improvement in rosacea severity, as 
measured by the Rosacea Severity Score, when compared to placebo cream.  Dichotomous data 
presented by Lee et al. did not show statistically significant improvement in rosacea severity, as 
measured by investigators’ global assessment of erythema and papules.  Dichotomous data from 
Weissenbacher et al. did not show statistically significant improvement in severity of clinical 
rosacea signs (erythema, papules, scaling, and pustules) as measured by the Rosacea Severity 
Score and the Subjective Severity Score after use of topical 1% pimecrolimus cream.  
 
CONCLUSIONS: Dichotomous data presented by Karabulut et al., Weissenbacher et al., and 
Lee et al. did not show the application of topical 1% pimecrolimus cream to cause statistically 
significant improvement in rosacea severity.  Based on this finding, all three studies indicate that 
topical 1% pimecrolimus cream is not more efficacious in improving rosacea severity when 
compared to placebo cream or an untreated portion of the face.  
 
KEY WORDS: Rosacea, Pimecrolimus, Elidel 
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INTRODUCTION 
Rosacea is a common, chronic inflammatory disease affecting the face that occurs 
primarily between the ages of thirty and fifty.  Rosacea has both a neurovascular presentation, as 
evidenced by erythema, telangiectasia, and flushing, as well as an acneiform presentation, 
manifested by the presence of papules and pustules.  In addition to the neurovascular and 
acneiform components, certain forms of rosacea have a glandular presentation involving 
hyperplasia of the nasal soft tissue known as rhinophyma.  Common sites of rosacea distribution 
are on the cheeks, nose, and chin.  Rosacea is characterized by periods of remissions and relapses 
which are treated symptomatically, to varying degrees of success, with different topical and 
systemic medications and therapies.
5
 
In terms of clinical relevance to Physician Assistants in practice, rosacea is a prevalent 
condition that is likely to be encountered by practitioners in almost all primary care settings.  It is 
estimated that fourteen million Americans have rosacea.  While the number of primary care 
office visits associated with rosacea each year has not be formally analyzed in the medical 
literature, the chronic nature of rosacea, as well as the tendency for the condition to flare and 
remit over an adult’s lifetime, is likely associated with recurrent patient visits.  Long term 
treatment for chronic rosacea flares can also be a costly endeavor for the patient.  One study by 
Thomas et al. found the financial cost of standard topical rosacea medications, systemic 
antibiotics, isoretinoin, and topical immunomodulators to be significant, ranging from $60.90 per 
success using metronidazole 1% gel once daily to $152.25 per success using azelaic acid 20% 
cream twice daily. Furthermore, these cost estimations do not include the additional expense of 
office visits to the dermatologist or other primary care provider.  Laser treatment for rosacea is
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often considered to be a cosmetic procedure and is therefore not commonly covered by 
insurance, resulting in notable out-of-pocket cost for the patient.
6
 
The current standard of treatment for rosacea is topical 0.75% to 1% metronidazole 
creams, lotions, and gels applied once daily.  Topical 1% clindamycin, in the same vehicle 
forms, can be used twice daily if metronidazole is not tolerated.  In patients who only exhibit a 
partial response to topical antibiotic treatment, sulfur-sodium sulfacetamide-containing topical 
treatments may be used, as well as topical benzoyl peroxide for control of persistent pustular 
presentations. When topical therapy proves inefficacious, systemic therapies such as tetracycline 
250-500 mg orally twice daily on an empty stomach may be used.  Cases that are refractory to 
tetracycline may be aided by the use of oral minocycline or doxycycline 50-100 mg daily to 
twice daily.
5
 
 It is known that patients with rosacea often report exacerbation of rosacea symptoms 
with ingestion of spicy food, hot drinks, or alcohol, exposure to sunlight, exposure to extreme 
heat or cold, exercise, and during emotional periods. These activities are thought to cause the 
release of vasoactive mediators, resulting in vasodilation and the subsequent flushing associated 
with rosacea.  A concrete, definitive etiopathogenesis for rosacea remains unknown at the current 
time, but pathophysiology research on the mechanics of rosacea suggests that immune or 
inflammatory factors such as eicosanoids, nitric oxide, and proinflammatory cytokines may play 
a pivotal role in rosacea symptomatology.
2  
Based on this pathophysiological research, it has 
been hypothesized that anti-inflammatory and/or immunomodulating agents may be effective 
methods of treating rosacea. 
Pimecrolimus is a calcineurin inhibitor and ascomycin macrolactam derivative that has 
immunomodulatory and anti-inflammatory effects.  Commercially marketed under the name 
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Elidel, pimecrolimus is administered in the form of a 1% concentration topical cream.  Topical 
1% pimecrolimus cream works by selecting target T-lymphocytes and mastocytes, and inhibiting 
the production and release of inflammatory cytokines such as tumor necrosis factor-alpha, 
interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, and IL-10.
2
  In addition, topical 1% pimecrolimus is 
thought to function by blocking expression of chemomodulators that activate inflammatory T-
cells in the body.  Based on the known immunomodulating effects of pimecrolimus and the 
suspected underlying inflammatory and immunological pathophysiology of rosacea, topical 
pimecrolimus has been investigated as a potential treatment to reduce the incidence and severity 
of rosacea symptoms. 
OBJECTIVE 
The objective of this systematic review is to determine whether or not, “Is topical 1% 
pimecrolimus cream an effective treatment for rosacea?”  A 2007 Cochrane Review of existing 
medical literature found topical 1% pimecrolimus cream to be significantly more effective than 
vehicle/placebo cream in the short term (<6 weeks) and long-term (>6 weeks) treatment of atopic 
dermatitis.
1
  Although the pathophysiology of both rosacea and atopic dermatitis is thought to 
involve inflammatory and immunologic responses in T-cells, a meta-analysis of the efficacy of 
1% pimecrolimus on rosacea has not been performed to date.   
METHODS 
A detailed search was completed by the author, using the search engines MEDLINE, 
OVID, and the Cochrane Database of Systematic Reviews.  The key words, “Pimecrolimus,” 
“Elidel,” and “Rosacea” were used in combination to search for English-language articles.  All of 
the resulting articles from the search were published in peer-reviewed journals between 1996 and 
2010.  The articles were selected based on importance of the outcomes to the patient (i.e. Patient 
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Oriented Evidence that Matters, or POEMS).  Studies that were included were those that were 
randomized, controlled studies, published after 1996 focusing on a patient oriented outcome for 
adults aged 18 or older.  Excluded studies were those in which the subjects were under the age of 
18 and/or articles that were published before 1996.  Randomized control trials (RCTs) were 
searched and selected based on the evidence that they focused on a patient population over 18 
years of age that had been clinically diagnosed with rosacea, as well as the evidence that the 
studies involved application of topical 1% pimecrolimus as the treatment intervention.  
Furthermore, only those articles that compared topical 1% pimecrolimus to the use of placebo 
cream or to the use of no cream at all were included in this review.  Based on the aforementioned 
criteria, three investigator-blind, randomized, placebo-controlled clinical trials were selected and 
included in this review.  Table 1 delineates the demographics of the studies included in this 
review.   
The study by Karabulut et al. reported statistics based on the Rosacea Severity Score, 
Visual Analog Scale (VAS), and Total Rosacea Severity Score (i.e. sum of individual Rosacea 
Severity Scores).  The study by Lee et al. reported statistics based on a VAS assessment as well 
as the investigators’ global assessment of erythema, papules, total inflammatory lesion count, 
and proportion of affected areas after 1, 2, 4, and 8 weeks and at baseline visit.  The study by 
Weissenbacher et al. reported statistics based on the Rosacea Severity Score, a VAS Subjective 
Severity Score, and a Dermatology Life Quality Index (DLQI).  For this review, selected 
dichotomous data from the Karabulut et al. and Weissenbacher et al. studies were interpreted into 
numbers needed to treat (NNT), while selected dichotomous data reported in the Lee et al. study 
were interpreted into numbers needed to harm (NNH).   
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Table 1.  Characteristics of Studies Included in Systematic Review of the Efficacy of 1% 
Topical Pimecrolimus Cream Versus Placebo in the Treatment of Rosacea 
Study Type # of 
Pts 
Age Inclusion 
Criteria 
Exclusion Criteria W/D Intervention 
Karabulut, 
2008  
(1) 
RCT 
(Investiga- 
tor blind, 
randomiz-
ed placebo 
controlled, 
split-face 
trial) 
25 23-60 
y.o. 
Adult 
rosacea 
patients 
w/ 
bilateral 
papulopu-
stular 
rosacea 
lesions 
 
No 
extrafacial/ocular 
lesions, pregnant or 
breastfeeding, 
hypersensitivity to 
Elidel, viral or 
malignant disease, 
severe ocular 
rosacea or severe 
flare-up reaction in 
the past, previous 
rosacea tx 4 weeks 
prior entry of into 
study 
N/A Split-face 
application 
of 1% 
topical 
pimecrolim-
us cream 
(Elidel) for 
4 weeks 
 
Lee, 2008 
(2) 
RCT 
(Investiga-
tor blind, 
randomiz-
ed, split-
face trial) 
18 Mean 
age 
43.9 
y.o. 
+/- 
15.9 
yrs. 
At least 18 
y.o.,  
diagnosed 
with 
steroid-
induced 
rosacea, 
previous 
hx of 
topical 
corticoste-
roid use 
for >2 
weeks 
No severe skin 
lesions requiring 
systemic tx other 
than antihistamine, 
acne vulgaris, 
debilitating medical 
disorders, use of 
HRT or oral 
corticosteroid, 
previous facial laser 
tx or surgical 
procedures 4 weeks 
prior to study 
enrollment, 
pregnant and 
lactating women 
3 Use of 1% 
pimecrolim-
us cream on 
one half of 
the subject’s 
face for 2 
weeks 
(2x/day) 
followed by 
6 weeks of 
1% 
pimecrolim-
us cream 
application 
on the 
whole face 
(2x/day) 
Weissenb-
acher, 
2007 
(3) 
RCT 
(Random-
ized 
vehicle-
controlled, 
double-
blind trial) 
40 36-76 
y.o. 
Pts with 
papulopu-
stular 
rosacea 
Specific exclusion 
guidelines were not 
delineated in paper 
N/A Daily 
application 
of a 1% 
pimecrolim-
us cream to 
the face B/L 
for tx of 
papulopust-
ular rosacea 
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OUTCOMES MEASURED 
 The primary outcomes measured in all three studies were rosacea severity and 
improvement as quantified by the National Rosacea Society Expert Committee’s Rosacea 
Severity Score system.
8
  The Rosacea Severity Score assesses the severity of four key rosacea 
symptoms (i.e. erythema, papules, scaling, pustules) and rates them on a scale of 0 to 3, with 0 
representing a complete absence of symptoms, 1 representing mild symptoms, 2 representing 
moderate symptoms, and 3 representing severe symptoms.  Karabulut et al. also examined Total 
Rosacea Severity Score by analyzing the sum of various individual severity assessments.   
All three studies involved Subjective Severity Assessment of rosacea using some form of 
a Visual Analog Scale (VAS).  Karabulut et al. performed a subjective severity assessment of 
each subject’s rosacea severity using VAS on a 0 to 10 mm scale. The study by Lee et al. had 
each subject conduct his/her own VAS assessment of the severity of his/her facial lesions and 
pruritus on a 0 to 100 scale (where 0 is absence of symptoms and 100 is severe).  Weissenbacher 
et al. performed a subjective severity assessment using a VAS on a scale of 0 mm to 100 mm 
(where 0 is “no skin changes” and 100 is “very severe skin changes”).  Rosacea severity and 
improvement were also measured via an assessment of erythema, papules, total inflammatory 
lesion count, and proportion of affected areas after 1, 2, 4, and 8 weeks and at baseline visit via 
Investigators’ Global Assessment of Severity.3   
RESULTS 
 The results, as they pertain to the measured outcomes, were presented primarily as 
dichotomous data in each of the three studies and analyzed as dichotomous data.  While three 
participants withdrew from the Lee et al. study, and one participant withdrew from the Karabulut 
et al. study, the data from each study were presented as an intention to treat analysis. 
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 Karabulut et al. reported rates of rosacea severity improvement as 0.5416% and 0.125% 
in the experimental and control group respectively.  This difference was not statistically 
significant as p-values were not provided for this data.  The relative benefit increase (RBI) was 
calculated to be 3.33%, while the absolute benefit increase (ABI) was calculated as 0.4166%.  
Based on these calculations, the number needed to treat (NNT) for this study was 2.4 using 
topical 1% pimecrolimus cream.  This is clinically important in that, for every 2.4 patients 
treated with 1% pimecrolimus cream, 1 more patient had improved rosacea as compared to the 
control group (Table 2).   
 Weissenbacher et al. reported rates of rosacea severity improvement as 0.32% and 0.37% 
in the experimental and control group respectively.  This difference was not statistically 
significant as p-values were not provided for this data.  The relative benefit increase (RBI) was 
calculated to be 0.135%, while the absolute benefit increase (ABI) was calculated to be -0.05%.  
Based on these calculations, the number needed to treat (NNT) for this study was -20.0.  This is 
clinically significant in that, for every 20 patients treated with the 1% pimecrolimus cream, 1 
patient fewer had improved rosacea compared to the control (Table 2).   
 Lee et al. reported rates of rosacea severity improvement as 0.2% and 0.0% in the 
experimental and control group respectively.  The difference was not statistically significant as 
p-values were not provided for this data.  The relative risk increase (RRI) was calculated to be 
0.0%, while the absolute risk increase (ARI) was calculated to be 0.2%.  Based on these 
calculations, the number needed to harm (NNH) for this study was 5.  This is clinically important 
because for every 5 patients treated with 1% pimecrolimus cream, 1 more patient had worsened 
rosacea symptoms as compared to the control group (Table 3).  The study by Lee et al. was 
unique in that it specifically analyzed the effect of 1% topical pimecrolimus on steroid-induced 
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rosacea as opposed to idiopathic rosacea.  It is also important to note that there were pieces of 
continuous data discussed in the Lee et al. study (i.e. results of the investigator’s global 
assessment of erythema and papules, lesion counts of papules and pustules, and percentage of 
facial areas involved measured at 1, 2, 4, and 8 weeks from baseline) that may suggest a 
significant therapeutic role for 1% pimecrolimus in the treatment of steroid-induced rosacea. 
However, the aforementioned pieces of continuous data could not be converted to dichotomous 
data for the purpose of this review and were therefore not included in the analysis. 
Table 2.  Efficacy of Topical 1% Pimecrolimus in Improvement of Rosacea - NNT 
Study Control 
Event Rate 
(CER) 
Experimental 
Event Rate 
(EER) 
Relative 
Benefit 
Increase 
(RBI) 
Absolute 
Benefit 
Increase 
(ABI) 
Number 
Needed to 
Treat (NNT) 
Karabulut, 
2008 
0.125% 0.5416% 3.33% 0.4166% 2.40 
Weissenbacher, 
2007 
0.37% 0.32% 0.135% -0.05% -20.0* 
* This negative value for NNT indicates that for every 20 patients treated with the experimental 
treatment (i.e. topical 1% pimecrolimus cream), 1 patient fewer had improved rosacea compared 
to the control.  P-values and 95% CI were not provided for the dichotomous data presented in 
the studies. 
 
Table 3.  Efficacy of Topical 1% Pimecrolimus in Improvement of Rosacea - NNH 
Study Control Event 
Rate (CER) 
Experimental 
Event Rate 
(EER) 
Relative Risk 
Increase 
(RRI) 
Absolute Risk 
Increase 
(ARI) 
Numbers 
Needed to 
Harm (NNH) 
Lee, 2008 0% 0.2% 0% 0.2% 5* 
* P-values and 95% CI were not provided for the dichotomous data presented in the study. 
  
In terms of adverse effects encountered by subjects in the studies included in this 
analysis, Lee et al. reported that 20% of subjects (i.e. three of the fifteen subjects involved in the 
study) experienced side-effects like burning or stinging at the site of pimecrolimus application or 
hyperpigmentation of an initially inflamed area of skin prior to pimecrolimus application.  
Notably, no patients participating in the Lee et al. study reported an exacerbation of their rosacea 
signs after application of the pimecrolimus.  Side effects associated with treatment in the 
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Karabulut et al. study included mild and transient local irritation of the skin. Three patients in 
this study complained of transient stinging/burning/itching of the skin lasting 5 to 10 minutes 
after application of pimecrolimus during the first 5 to 7 days of the trial.  Two patients 
complained of lip dryness during the trial.  One patient ultimately withdrew from the study at the 
second week due to a “severe flare up reaction.”2 In the Weissenbacher et al. study, one patient 
complained of facial skin tightness and another patient complained of pruritus. 
DISCUSSION 
Pimecrolimus is a topical calcineurin inhibitor and immunomodulator.  Clinically 
indicated for the treatment of atopic dermatitis by the U.S. Food and Drug Administration, 
pimecrolimus acts by penetrating the inflamed epidermal layer of the skin and inhibits the 
transcription and activation of proinflammatory cytokines including IL-2, IL-4, IL-10, and 
interferon gamma.  This ultimately prevents the immunologic activation of T-cells.  Adverse 
reactions to the drug include headache, burning at the site of application, and nasopharyngitis.  
According to the U.S. Black Box warning, topical calcineurin inhibitors have been associated 
with rare cases of skin malignancy and lymphoma, and should therefore be used only in short-
term and intermittent treatment regimens with application to limited surface areas.  Further, 
pimecrolimus is not recommended for use in children under the age of 2 years.  
Contraindications for use of the drug include hypersensitivity to pimecrolimus or any other 
components in its formulation.
4
   
The studies chosen for analysis had several limitations.  Each study assessed the 
qualitative severity of rosacea via the National Rosacea Society Expert Committee guidelines. 
However, due to the uncontrollable triggers of rosacea (i.e. stress, sunlight, menstruation, hot 
environments), the therapeutic impacts of the pimecrolimus may have been altered, which in turn 
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may have affected the rosacea severity of each patient and his/her Rosacea Severity Score.  In 
the study by Lee et al., subjects were given the opportunity to assess their own rosacea severity 
via a visual analog scale.  Based on the subjective nature of self-assessment, these visual analog 
scale scores may not have been well-standardized or controlled.  In the Lee et al. study, three 
subjects experienced adverse effects (i.e. burning, stinging) and one patient complained of 
postinflammatory hyperpigmentation, and three subjects dropped out early in the study for 
reasons including noncompliance, loss of follow-up, and protocol violations.  This change in 
subject enrollment may have impacted the accuracy of the study outcomes.  The study by 
Weissenbacher et al. also utilized a placebo cream for the control group that may have had 
emollient properties to reduce skin scaling and dryness.  The therapeutic effects of this placebo 
vehicle cream may have caused improvement in rosacea severity symptoms, thereby impacting 
the significance of the rosacea severity improvement in the experimental group. 
CONCLUSION 
The studies reviewed demonstrate that the topical application of 1% pimecrolimus cream 
is not an effective treatment for rosacea in that it is not shown to cause a statistically significant 
improvement in the severity of rosacea.  There were multiple methods used to assess rosacea 
severity in each of the studies analyzed, including the Rosacea Severity Score set forth by the 
National Rosacea Society Expert Committee, Visual Analog Scores with differing numerical 
scales and means of assessment (i.e. self-assessment and investigator assessment), and an 
investigator assessments of global rosacea severity.  The use of such a variety of assessment 
tools makes it difficult to do side-by-side comparisons of results (i.e. improvement in rosacea 
severity) from multiple studies as rosacea severity is qualitatively and quantitatively analyzed by 
differing parameters.  Future studies evaluating the efficacy of pimecrolimus in reduction of 
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rosacea symptoms should use one central method of assessment, such as the Rosacea Severity 
Score set forth by the National Rosacea Society Expert Committee, to evaluate results.  Future 
investigations may be warranted in the investigation of the effects of 1% pimecrolimus cream on 
steroid-induced rosacea as compared to the effects of 1% pimecrolimus cream on rosacea 
occurring in non-steroid users.  In addition, future tests may focus experimental methods on the 
split-face method of experimental control, so as to evaluate the effects of pimecrolimus versus 
placebo on the same face with the same baseline severity of rosacea symptoms.  
  
 
 
REFERENCES 
1. Ashcroft DM, Chen LC, Garside R, Stein K, Williams HC. Topical pimecrolimus for 
eczema. Cochrane Database Syst Rev. 2007;(4):CD005500. 
DOI:10.1002/14651858.CD005500.pub2. 
2. Karabulut AA, Izol Serel B, Eksiolgu HM. A randomized, single-blind, placebo-controlled, 
split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad 
Dermatol Venereol. 2008;22(6):729-734. 
3. Lee DH, Li K, Suh DH.  Pimecrolimus 1% cream for the treatment of steroid-induced 
rosacea: an 8 week split-face clinical trial. Br J Dermatol. 2008;158(5):1069-1076. 
4. Lexi-Comp ONLINE [database online]. Hudson, OH: Lexi-Comp Inc; 2010. 
http://online.lexi.com. Accessed November 21, 2010.   
5. McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment 2010. 49th ed.  
New York, NY: McGraw-Hill Medical; 2010.   
6. Thomas K, Yelverton CB, Yentzer BA, et al. The cost-effectiveness of rosacea treatments. J 
Dermatol Treatment. 2009;20(2):72-75. 
7. Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular 
rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol.  
2007;156(4):728-732. 
8. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the 
National Rosacea Society Expert Committee on the classification and staging of rosacea. J 
Am Acad Dermatol. 2004;50(6):901-912. 
